

# The Journey of Macromolecular Crystallography in Pharmaceutical Discovery Research at Abbvie and BMS.

J Muckelbauer<sup>1</sup>, V Stoll<sup>2</sup>

<sup>1</sup>*Molecular Structure & Design, Bristol-Myers Squibb* <sup>2</sup>*Abbvie, Inc.*

*jodi.muckelbauer@bms.com*

Although many pharmaceutical companies had established macromolecular crystallography groups by 1988, the crystal structures of HIV Protease in 1989 demonstrated the important utility of structure and firmly established the role of macromolecular crystallography in the process of drug design. Recognizing the potential of structure based drug design, companies made substantial investments in infrastructure and personnel initially and they continue to invest to this day. In this presentation, we will share our 30-year journey. Topics will focus on how macromolecular crystallography was established at our companies and how our groups have evolved over the years to increase efficiency and productivity. We will also provide structure based drug design examples that highlight the important role of structure in the process of drug discovery.